There are currently 15 active clinical trials seeking participants for Anemia research studies. The states with the highest number of trials for Anemia participants are California, Texas, Florida and New York.
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
NCT04455841
Recruiting
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: City of Hope National Medical Center, Duarte, California +33 locations
Conditions: Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Register for Updates
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414
Recruiting
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: University Of California Los Angeles, Los Angeles, California +184 locations
Conditions: Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Register for Updates
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
NCT05732961
Recruiting
The purpose of the study is to see if participants with anemia due to their type of MDS or MDS/MPN will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care, and what effect, good and/or bad, luspatercept has on them and their anemia due to MDS or MDS/MPN. The safety and tolerability of luspatercept will also be evaluated in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia
Register for Updates
Pilot Feasibility Study of a Novel Non-invasive Device for Diagnosis of Anemia
NCT06159348
Recruiting
In low-resource areas of the world, anemia screening relies on analyzing a blood sample and is generally carried out in health facilities. Current anemia screening approaches have not yielded satisfactory results due to critical limitations including lack of a) reliable access to laboratory facilities, b) reliable non-invasive out-of-hospital screening tools for community health-workers, c) integration of anemia data across health systems and d) distinction between hemolytic and nutritional caus... Read More
Gender:
All
Ages:
Between 17 years and 70 years
Trial Updated:
05/08/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Anemia
Register for Updates
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
NCT03850964
Recruiting
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo [sugar - inactive pill], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US De... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/28/2024
Locations: University of California - Los Angeles, Los Angeles, California +10 locations
Conditions: Hereditary Hemorrhagic Telangiectasia, Anemia, Epistaxis, Nosebleed, HHT
Register for Updates
Study of DISC-0974 in Participants With Myelofibrosis and Anemia
NCT05320198
Recruiting
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +13 locations
Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Register for Updates
129Xe MRI Cardiopulmonary
NCT06038630
Recruiting
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Register for Updates
Scoliosis Iron Supplementation Study
NCT06042699
Recruiting
This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in adolescents undergoing scoliosis surgery. Research Question(s)/Hypothesis(es): Primary Iron supplementation will reduce the incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing sp... Read More
Gender:
All
Ages:
Between 12 years and 19 years
Trial Updated:
01/31/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Adolescent Idiopathic Scoliosis, Neuromuscular Scoliosis, Perioperative/Postoperative Complications, Iron Deficiencies, Anemia, Spinal Fusion, Postoperative Cognitive Dysfunction
Register for Updates
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
NCT05126901
Recruiting
The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety and tolerability of ferric maltol oral suspension in children 1 month to less than 2 years, in the treatment of iron deficiency anaemia during the 12 weeks treatment period.
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
12/18/2023
Locations: The Center for Clinical Trials, Saraland, Alabama +24 locations
Conditions: Anemia, Iron-deficiency
Register for Updates
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
NCT05634005
Recruiting
Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will not be visible to the control. Both groups still have access to information about best practices: local clinical transfusion guidelines are ava... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Register for Updates
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164
Recruiting
Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of a transfusion-transmissible infection. The objectives and design of... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
09/11/2023
Locations: Phoenix Children's Hospital (PCH), Phoenix, Arizona +11 locations
Conditions: Anemia
Register for Updates
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
NCT05800600
Recruiting
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/23/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Anemia
Register for Updates